---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-25-000123"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:22:37.176351+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elicio Q3 net loss $10.1M ($0.60/sh); Phase 2 DFS analysis pushed to 1H 2026 on fewer events

## Summary
- Phase 2 AMPLIFY-7P: fewer disease progressions/deaths than projected; event-driven primary DFS analysis now expected 1H 2026.
- Raised ~$11.1M gross via ATM since Q3 start; cash $20.6M at Sep 30, extending runway through Q2 2026.
- Q3 net loss $10.1M ($0.60/sh) vs $18.8M ($1.39) YoY; R&D expense down to $5.0M from $7.2M.
- IDMC recommended continue Phase 2 without modifications; after DFS analysis, will request End of Phase 2 FDA meeting.

## SEC filing metadata
- accession: 0001601485-25-000123
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/0001601485-25-000123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/angn-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-25-000123
- JSON: https://secwatch.observer/filing/0001601485-25-000123.json
- Plain text: https://secwatch.observer/filing/0001601485-25-000123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.